Asher Elad, Hod Hanoch, Buber Jonathan, Beigel Roy, Vatury Ori, Matetzky Shlomi
Heart Institute, Sheba Medical Center, Tel Hashomer, Israel.
Harefuah. 2011 Feb;150(2):131-5, 206, 205.
Platelet activation and aggregation play a major role in the pathogenesis of acute coronary syndrome (ACS) and thrombotic complications following percutaneous coronary interventions (PCI). Antiplatelet therapy with aspirin (ASA) and/or clopidogrel remains one of the most effective therapies for the treatment of ACS and prevention of thrombotic complications following PCI. Nevertheless, not all patients achieve the desired laboratory and/or clinical effect following antiplatelet therapy. These patients have been termed "aspirin resistant" or "clopidogrel resistant". In recent years, several studies regarding clopidogrel resistance have been conducted, and a number of pharmacological therapies, together with new treatments, have been suggested. This review aims to provide an overview of the epidemiology, prevalence, clinical significance and potential solutions regarding clopidogrel resistance.
血小板活化和聚集在急性冠状动脉综合征（ACS）的发病机制以及经皮冠状动脉介入治疗（PCI）后的血栓形成并发症中起主要作用。使用阿司匹林（ASA）和/或氯吡格雷进行抗血小板治疗仍然是治疗ACS和预防PCI后血栓形成并发症最有效的疗法之一。然而，并非所有患者在接受抗血小板治疗后都能达到理想的实验室和/或临床效果。这些患者被称为“阿司匹林抵抗”或“氯吡格雷抵抗”。近年来，已经开展了多项关于氯吡格雷抵抗的研究，并提出了一些药物治疗方法以及新的治疗手段。本综述旨在概述氯吡格雷抵抗的流行病学、患病率、临床意义和潜在解决方案。
